BGB-A317-213

Active, not recruiting

Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma

Beigene Study ID info

BGB-A317-213

ClinicalTrials.gov ID info

China Drug Trials ID info

CTR20211753

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

No Study Documents

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

No Study Documents